Clinical Trial

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-01.
Trial Details
NCT Number NCT07513181
Lead Sponsor Athos Therapeutics Inc
Conditions Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Enrollment 120 participants
Start Date 2026-06
Primary Completion 2028-12-14 (estimated)
Study Completion 2028-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-08